Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.59 |
| ▸ | CYP3A5 | P20815 | 5/20 | 0.59 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473850 | 0.97 | CYP19A1 (0.64) | CYP19A1CYP3A4CYP3A5AHRRORC | |
| SCHEMBL8986531 | 0.85 | AHR (0.57) | CYP19A1CYP3A4CYP3A5AHR | |
| SCHEMBL29205 | 0.85 | CA4 (0.54) | AHR | |
| SCHEMBL28797 | 0.85 | CA4 (0.54) | AHR | |
| SCHEMBL913686 | 0.85 | CYP19A1 (0.72) | CYP19A1CYP3A4CYP3A5RORCKCNA5 | |
| SCHEMBL30927949 | 0.83 | CYP19A1 (0.53) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL29226492 | 0.83 | CYP19A1 (0.53) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL30927957 | 0.83 | CYP19A1 (0.53) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL29226497 | 0.83 | CYP19A1 (0.53) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL11627640 | 0.80 | CYP19A1 (0.51) | CYP19A1CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| EP-0918514-B9 | TRIARYL METHANE COMPOUNDS FOR THE TREATMENT OF CANCER, ACTINIC KERATOSIS AND KAPOSI'S SARCOMA | HARVARD COLLEGE (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-0918514-B1 | TRIARYL METHANE COMPOUNDS FOR THE TREATMENT OF CANCER, ACTINIC KERATOSIS AND KAPOSI'S SARCOMA | HARVARD COLLEGE (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20040127464-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | BRUGNARA CARLO (US) | 2004-07-01 | — | — | US | disclosed |
| US-20030119784-A1 | Method for reducing chloride secretion by intestinal epithelial cells in situ: use of triaryl methane compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | disclosed |
| US-6495567-B1 | REDUCING CHLORIDE SECRETION; PREVENTING DEHYDRATION, ACIDOSIS, DEATH AND IMPAIRED GROWTH | BETH ISRAEL DEACONESS MEDICAL CENTER | 2002-12-17 | — | — | US | disclosed |
| US-20020119953-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | BRUGNARA CARLO (US) | 2002-08-29 | — | — | US | disclosed |
| US-6331564-B1 | TREATING DIARRHEA CAUSED BY INFLAMMATORY BOWEL DISEASE, AUTOIMMUNE DISEASES SUCH AS LUPUS, GLOMERULONEPHRITIS | ION PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-0918514-A4 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | HARVARD COLLEGE (US) | 2001-05-09 | — | — | EP | disclosed |
| CN-1251037-A | Triarylmethane compounds for sickle cell disease | HARVARD COLLEGE (US) | 2000-04-19 | — | — | CN | disclosed |
| US-6028103-A | Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0918514-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997034589-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119784-A1 | Method for reducing chloride secretion by intestinal epithelial cells in situ: use of triaryl methane compounds | SLC10A2, VIP, CLCN2 | CYP19A1 2983/4885CYP3A4 416/4885CYP3A5 277/4885 |
| US-20040127464-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | CCNO, HPGDS, TSPO | CYP19A1 3634/4885CYP3A4 2748/4885CYP3A5 3027/4885 |
| US-20020119953-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | CCNO, HPGDS, TSPO | CYP19A1 3634/4885CYP3A4 2748/4885CYP3A5 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.